Search

Displaying results 1141 - 1150 of 10000 in total
  1. Drug

    Canagliflozin

    go.drugbank.com/drugs/DB08907
    ApprovedInvestigational

    It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type

    Mixtures: VOKANAMET 150 MG/500 MG, FILM-COATED TABLETS 150 MG / 500 MGCategories: Heterocyclic Compounds, 1-Ring
  2. Drug

    Selenium

    go.drugbank.com/drugs/DB11135
    ApprovedInvestigationalVet approved

    Selenium is a trace metal in the human body particularly important as a component of glutathione peroxidase, an important enzyme in the prevention of cellular damage by free radicals and reactive oxygen

    Mixtures: PreQue 10, PreQue 10Products: selenase ® 100 micrograms, solution for injection (50 micrograms/ml), SELENASE® 50 MICROGRAMS/ML - ORAL SOLUTION
  3. Drug

    Ornidazole

    go.drugbank.com/drugs/DB13026
    Investigational

    Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery.

    Mixtures: ORNISASIN 500 MG/500 MG FILM TABLET, 10 ADET, ORCIPOL 500 MG/500 MG FILM TABLET, 10 ADETCategories: Heterocyclic Compounds, 1-Ring
  4. Drug

    Palbociclib

    go.drugbank.com/drugs/DB09073
    ApprovedInvestigational

    [A176810] Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as key regulators of cell growth.

    Synonyms: 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-oneProducts: REAMPLA 100 MG KAPSÜL, 7 KAPSÜL, REAMPLA 100 MG KAPSÜL, 21 KAPSÜL
  5. Pathway

    De Novo Triacylglycerol Biosynthesis TG(10:0/10:0/10:0)

    smpdb.ca/view/SMP0015899
    Metabolic

    A triglyceride (TG, triacylglycerol, TAG, or triacylglyceride) is an ester derived from glycerol and three fatty acids. Triglycerides are the main constituents of body fat in humans and other animals, as well as vegetable fat. They are a...

    Drugs: NADH · sn-glycerol 3-phosphate · Dihydroxyacetone phosphate
  6. Pathway

    Cardiolipin Biosynthesis CL(10:0/10:0/10:0/12:0)

    smpdb.ca/view/SMP0175276
    Metabolic

    Cardiolipin biosynthesis occurs mainly in the mitochondria, but there also exists an alternative synthesis route for CDP-diacylglycerol that takes place in the endoplasmic reticulum.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  7. Pathway

    Cardiolipin Biosynthesis CL(10:0/10:0/10:0/14:0)

    smpdb.ca/view/SMP0175278
    Metabolic

    Cardiolipin biosynthesis occurs mainly in the mitochondria, but there also exists an alternative synthesis route for CDP-diacylglycerol that takes place in the endoplasmic reticulum.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  8. Pathway

    Cardiolipin Biosynthesis CL(10:0/10:0/10:0/22:0)

    smpdb.ca/view/SMP0175287
    Metabolic

    Cardiolipin biosynthesis occurs mainly in the mitochondria, but there also exists an alternative synthesis route for CDP-diacylglycerol that takes place in the endoplasmic reticulum.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  9. Pathway

    Cardiolipin Biosynthesis CL(8:0/10:0/10:0/10:0)

    smpdb.ca/view/SMP0226114
    Metabolic

    Cardiolipin biosynthesis occurs mainly in the mitochondria, but there also exists an alternative synthesis route for CDP-diacylglycerol that takes place in the endoplasmic reticulum.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  10. Drug

    Brolucizumab

    go.drugbank.com/drugs/DB14864
    ApprovedInvestigational

    Brolucizumab, also known as RTH258 or ESBA1008, is a monoclonal antibody indicated to treat neovascular age related macular degeneration. Brolucizumab was granted FDA approval in October 2019.

    Products: Xivubel 120 mg/ml Enjeksiyonluk Çözelti, 1 adet, Pagenax 120mg/ml Solution For Injection